When to stop, what the FDA labeling actually says, what happens with PCOS, and what to know about breastfeeding and weight regain after stopping.
GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — are now prescribed at scale to women of reproductive age. The primary indications are obesity and type 2 diabetes, but an increasing number of prescriptions are reaching women being treated for obesity-related polycystic ovary syndrome (PCOS) and insulin resistance, both of which are common causes of disrupted ovulation and reduced fertility.
This creates a genuinely complicated situation. Weight loss — including weight loss achieved through GLP-1 therapy — can meaningfully improve fertility in women with obesity and PCOS. At the same time, these medications carry FDA warnings against use during pregnancy, and the human data on their effects during early fetal development is very limited. The two things are true simultaneously, and navigating them requires clear information.
There is also a more immediate concern: as GLP-1 prescribing has expanded, women who believed they had reduced fertility have become pregnant while on these medications — including during periods when they were not actively trying to conceive. That is not a theoretical risk. It is happening, and it underscores why this topic warrants a careful, direct conversation with a healthcare provider.
This guide is informational, not medical advice. Family planning decisions involving GLP-1 medications are genuinely complex and depend on your individual health history, fertility situation, and weight management needs. The right source for a decision is your OB/GYN, reproductive endocrinologist, or prescribing clinician — not an internet guide. What follows is intended to help you understand the landscape and have a more informed conversation with them.
Both semaglutide and tirzepatide carry an FDA recommendation to discontinue the medication before a planned pregnancy. The current labeling for each medication states the following (in substance — always verify against the current package insert):
A key point that is sometimes misunderstood: the FDA guidance is to discontinue before conception — not after a positive pregnancy test. By the time a home pregnancy test turns positive, approximately 4–6 weeks of fetal development have already occurred. That early period is the most critical window for organogenesis. Stopping on the day of the positive test means the drug was present throughout the most sensitive developmental stages.
Important framing: The animal study findings are real, but context matters. "Fetal harm" in animal studies was observed at doses substantially above the doses used in human treatment. Current labeling does not state that exposure at human therapeutic doses causes specific, known fetal outcomes. What it states is that human data is insufficient to conclude there is no risk, and that the animal data provides enough concern to warrant precautionary discontinuation before conception. That is the appropriate framing — not "this drug definitely causes birth defects" and not "the animal data doesn't apply to humans."
The FDA's stop-before-conception windows are derived from the medications' elimination half-lives — the time it takes for drug concentration to fall by half. Understanding the pharmacokinetics helps explain why these windows are what they are.
The practical implication: if you are planning a pregnancy, the conversation with your prescriber should happen well in advance — ideally several months before you plan to begin trying to conceive. This creates time to plan the stop, allow clearance, and address the weight management transition before conception attempts begin.
Stopping the day of a positive pregnancy test is not the recommended approach. Depending on when conception occurred within a cycle, the drug would have been present for the entirety of the earliest and most sensitive developmental period.
For women with PCOS and obesity, GLP-1 medications present a particular set of considerations that are different from the general case. PCOS is the most common hormonal disorder in women of reproductive age, and obesity substantially worsens PCOS-related insulin resistance, androgen excess, and ovulatory dysfunction. Weight loss — by almost any means — is one of the most effective interventions for restoring ovulatory function in women with obesity-related PCOS.
Researchers have noted that GLP-1 medications may improve fertility-related markers in women with PCOS through multiple pathways: direct improvements in insulin sensitivity, reductions in androgen levels, and the general metabolic benefits of weight loss. Some studies have observed improvements in menstrual regularity and ovulatory frequency in women with PCOS treated with GLP-1 agonists, even at modest levels of weight loss.
This creates a specific and important risk that women on GLP-1 medications should understand:
Unintended pregnancy risk is real. Women who previously experienced irregular cycles or believed they had reduced fertility due to PCOS may find that GLP-1 therapy — through weight loss and improved ovulatory function — meaningfully changes their fertility status. Women who are sexually active and not planning a pregnancy should discuss contraception with their provider explicitly in the context of GLP-1 therapy. This is not a routine medication that can be treated as fertility-neutral.
Additionally, GLP-1 medications may affect the absorption of oral contraceptives by slowing gastric emptying. This is a conversation to have with your prescriber if you are using oral contraceptives while on a GLP-1 medication.
For women who are actively using GLP-1 therapy to address obesity-related fertility barriers, the conversation with a reproductive endocrinologist or OB/GYN should ideally happen before stopping the medication — not after. The transition off GLP-1 therapy, the timing of conception attempts, and the weight management strategy during pregnancy are all connected decisions that benefit from being made together.
Setting aside the weight-loss-mediated improvements in fertility discussed above, a separate question is whether GLP-1 medications have direct effects on egg quality, implantation, or early embryonic development in humans.
The honest answer is that available data is limited. GLP-1 receptors are expressed in reproductive tissues, including the ovaries and uterus, which means the pharmacological pathway exists for direct effects. Animal studies have identified GLP-1 receptor expression in these tissues and noted effects at supratherapeutic doses. However, at doses used clinically in humans, the animal data does not provide a clear picture of reproductive toxicity that would translate directly to anticipated human outcomes.
Human clinical trial data is sparse because, appropriately, women who are pregnant or planning to become pregnant are excluded from trials of these medications. The data that exists comes from:
What this means practically: The absence of well-characterized human data showing harm is not the same as evidence of safety. These are newer medications, the relevant trials did not include pregnant women, and the clinical registry data is still maturing. The appropriate posture for anyone making family planning decisions involving GLP-1 medications is to treat the data limitations as real, to follow the FDA labeling guidance conservatively, and to work closely with an OB/GYN or reproductive endocrinologist who is tracking the emerging literature.
As GLP-1 prescribing has expanded dramatically since 2023, accidental first-trimester exposure is occurring with meaningful frequency. This is an increasingly common clinical scenario, and there is a standard response protocol.
Both manufacturers maintain registries specifically to collect pregnancy outcome data from inadvertent exposures. Enrollment is voluntary but strongly encouraged — this data is how clinicians will eventually develop a clearer picture of actual risk at human therapeutic doses:
| Medication | Registry | Maintained By | Contact |
|---|---|---|---|
| Semaglutide (Ozempic, Wegovy) | Ozempic/Wegovy Pregnancy Registry | Novo Nordisk | 1-800-727-6500 or through your prescriber |
| Tirzepatide (Mounjaro, Zepbound) | Mounjaro/Zepbound Pregnancy Exposure Registry | Eli Lilly | 1-800-545-5979 or through your prescriber |
Registry contact information is subject to change. Your OB/GYN or prescriber can provide current enrollment details.
As of 2026, the outcome data from accidental exposures is not yet well-characterized. The registries are collecting data and results will emerge over time. There is not currently a published body of evidence showing that accidental first-trimester exposure at therapeutic doses causes specific, well-defined adverse fetal outcomes in humans. There is also not a body of evidence confirming safety. The data gap is real, and that framing — neither alarming nor reassuring, just genuinely uncertain — is the accurate one.
If you have inadvertently been exposed to a GLP-1 medication during pregnancy, communicate this clearly and honestly to your OB/GYN. Withholding this information makes it harder to provide appropriate monitoring and care.
The guidance on GLP-1 medications during breastfeeding is consistent across manufacturers: these medications are not recommended during breastfeeding.
The conversation about GLP-1 medications and breastfeeding is one to have with your prescriber and OB/GYN before delivery, not in the immediate postpartum period when decisions are harder to make thoughtfully. The relevant questions include:
Timing of restart: Because both semaglutide and tirzepatide have long half-lives, clinicians generally advise waiting until breastfeeding has fully ended — not just until you begin supplementing with formula — before restarting. The specific restart timing should be guided by your prescriber, who can account for your individual situation, the medication involved, and your clinical goals.
For many women reading this guide, the weight trajectory question is one of the most difficult parts of the GLP-1-and-fertility conversation. The medications work — that is the reason they were started. Stopping them to conceive, then going through pregnancy and potentially a breastfeeding period without them, creates a multi-year window where the weight management that supported fertility improvement may erode.
The STEP-4 trial — a randomized controlled trial examining weight regain after stopping semaglutide — found that approximately two-thirds of weight lost during active treatment was regained within 52 weeks of stopping. This is consistent with the broader literature on anti-obesity medication withdrawal: the weight tends to return because the underlying physiological drivers of obesity are still present and the behavioral adaptation to the medication's effects is not sustained without it.
This has specific implications for women who used GLP-1 therapy primarily to address obesity-related fertility barriers:
The weight trajectory challenge is not an argument against stopping GLP-1 medications to conceive. It is an argument for having this conversation explicitly and in advance, with an OB/GYN or reproductive endocrinologist who understands both the fertility goals and the weight management picture. A thoughtful plan might include:
See our GLP-1 Stopping Guide for more on managing the weight transition when coming off these medications for any reason.
This is not a decision protocol or a substitute for clinical guidance. It is a framework of questions that clinicians generally address with women who are on GLP-1 medications and considering pregnancy — offered here so you can come to that appointment with the right things in mind.
For semaglutide, the FDA-based guidance is 2 months before planned conception attempts begin. For tirzepatide, 1 month. These are minimum windows, not targets to optimize against — stopping earlier is not harmful. Ask your prescriber for their specific recommendation for your situation.
The transition off GLP-1 therapy is a good time to bring your OB/GYN fully into the picture — your weight history, the medications you have been on, your fertility history if any, and your goals. If you have PCOS or other fertility considerations, ask whether a referral to a reproductive endocrinologist is appropriate.
If you are stopping the GLP-1 medication ahead of planned conception attempts but are not yet actively trying to conceive, discuss contraception with your provider. As discussed above, improved fertility from weight loss is a real effect that may change your fertility status relative to what you experienced before treatment.
Your OB/GYN should know your complete medication history, including when you stopped the GLP-1 medication. If you have inadvertent first-trimester exposure, disclose this proactively. Enroll in the pregnancy registry if appropriate.
Discuss with your prescriber and OB/GYN: when after delivery and/or breastfeeding completion is it appropriate to restart? What are the clinical criteria? Who manages the restart — the OB/GYN, the original prescriber, or a new one? Having this conversation before delivery is much easier than in the immediate postpartum period.
The FDA-based guidance that clinicians generally follow is to stop semaglutide (Ozempic, Wegovy) at least 2 months before attempting to conceive, and tirzepatide (Mounjaro, Zepbound) at least 1 month before. These windows reflect the drugs' elimination half-lives plus a safety buffer. Stopping on the day of a positive pregnancy test is too late — fetal development has already been underway for 4–6 weeks by the time a home test turns positive. This timing should be planned and discussed with your OB/GYN or prescriber in advance, not managed independently.
The direct effects of GLP-1 medications on egg quality, ovulation, implantation, or early embryonic development in humans are not well-characterized — the available human data is limited because pregnant women are excluded from clinical trials. For women with obesity or PCOS, weight loss from GLP-1 therapy can improve ovulatory function and fertility, which is a real and documented effect. Some women who had difficulty conceiving have become pregnant while on these medications. Animal studies at supratherapeutic doses have shown developmental issues, but those doses are substantially above clinical therapeutic levels. The honest answer is that the data is still thin, and a conversation with a reproductive endocrinologist is the appropriate next step for anyone with specific fertility questions.
Discontinue the medication immediately and contact your OB/GYN. Inform your GLP-1 prescriber as well. Both Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide) maintain pregnancy registries — your OB/GYN can assist with enrollment, and participation helps build the data that will eventually give clinicians a clearer picture of risk at therapeutic doses. Accidental first-trimester exposure is occurring with increasing frequency as these prescriptions expand. Your OB/GYN has seen this scenario and can assess your situation appropriately. Do not delay contacting them.
GLP-1 medications are not recommended during breastfeeding. Human data on excretion into breast milk is very limited, and the general clinical principle is that mothers who are breastfeeding should avoid these medications until breastfeeding is complete or a decision to formula-feed has been made. Because semaglutide and tirzepatide have long half-lives — meaning drug levels persist for weeks after the last dose — the timing of a safe restart is not simply the day breastfeeding ends. Discuss the specific restart timeline with your prescriber.
Weight regain is a well-documented outcome after stopping GLP-1 medications. The STEP-4 trial found approximately two-thirds of lost weight returned within 52 weeks of stopping semaglutide. For women who used these medications to address obesity-related fertility barriers, the stop-conceive-pregnancy-breastfeed timeline can span 2–3 years without access to GLP-1 therapy. This is a real and important consideration that warrants a full conversation with your OB/GYN or reproductive endocrinologist — including a concrete plan for nutritional support during that window and for restarting after the reproductive episode is complete.